3,5-Dihydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)heptane

Multiplatform Metabolomics Investigation of Anti-Adipogenic Effects on 3T3-L1 Adipocytes by a Potent Diarylheptanoid.[Reference: WebLink]

Journal of Proteome Research, 2018:acs.jproteome.8b00028.

Obesity is fast becoming a serious health problem worldwide. Of the many possible anti-obesity strategies, one interesting approach focuses on blocking adipocyte differentiation and lipid accumulation to counteract the rise in fat storage. However, there is currently no drug available for the treatment of obesity that works by inhibiting adipocyte differentiation.
CONCLUSIONS:
Here we use a broad-based metabolomics approach to interrogate and better understand metabolic changes that occur during adipocyte differentiation. In particular, we focus on changes induced by the anti-adipogenic diarylheptanoid, which was isolated from a traditional Chinese medicine Dioscorea zingiberensis and identified as (3R,5R)-3,5-Dihydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)heptane (1). Targeted aqueous metabolic profiling indicated that a total of 14 metabolites involved in the TCA cycle, glycolysis, amino acid metabolism, and purine catabolism participate in regulating energy metabolism, lipogenesis, and lipolysis in adipocyte differentiation and can be modulated by diarylheptanoid 1. As indicated by lipidomics analysis, diarylheptanoid 1 restored the quantity and degree of unsaturation of long chain free fatty acids, and restored the levels of 171 lipids mainly from 10 lipid species in adipocytes. In addition, carbohydrate metabolism in diarylheptanoid 1 treated adipocytes further demonstrated the delayed differentiation process by flux analysis.
CONCLUSIONS:
Our results provide valuable information for further understanding the metabolic adjustment in adipocytes subjected to diarylheptanoid 1 treatment. Moreover, this study offers new insight into developing anti-adipogenic leading compounds based on metabolomics.